Macroaxis: Personalized Investing
Simple Personalized Investing

S&P 500   1,667   17.00  Index Moved Up 1.03%
FNMFO FNMFO 096770 KDDIF Stores Marketing Munis Macroaxis 15 
United States  USA  |  Check Insiders


Processing
Processing. Please wait...

QRxPharma Cash and Equivalents

 
 Companies |  Insiders  | Dashboard  
     

Cash and Equivalents breakdown for QRxPharma

Cash or Cash Equivalents are the most liquid of all assets found on company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

QRxPharma

Cash

=

Greens

+

Liquids

=
32.37 M
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually 3 months).
Compare QRxPharma to competition
In accordance with recently published financial statements QRxPharma Pty Ltd has 32.37 M in Cash and Equivalents. This is much higher than that of sector, and significantly higher than that of Cash and Equivalents industry, The Cash and Equivalents for all stocks is over 1000% lower than the firm.

Filter other Stocks by Cash and Equivalents

Specify Market Cap
Select Cash and Equivalents Range
Current Range 
Indicate Industry
Click to run this filter
 Run Equity Filter
Filter Other Equities
  

Cash and Equivalents Comparison

QRxPharma is currently under evaluation in cash and equivalents category among related companies.
Follow QRxPharma Cash and Equivalents with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add QRxPharma to your reader
 
    
QRXPY United States OTC
QRxPharma Pty Ltd
Traded on OTC Market
    
    

Other QRxPharma Fundamentals

Return On Equity(88.89) %
Return On Asset(51.36) %
Current Valuation225.31 M
Shares Outstanding28.86 M
Price to Book9.76 times
Price to Sales616 times
Revenue422.74 K
EBITDA(22.74 M)
Net Income(21 M)
Cash and Equivalents32.37 M
Cash per Share1.12 times
Current Ratio4.90 times
Book Value Per Share0.92 times
Cash Flow from Operations(14.76 M)
One Year High11.72
One Year Low5.21
Earnings Per Share(0.79) times
Number of Employees14
Market Capitalization257.68 M
Probability Of Bankruptcy43.15 %


 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium